Case Reports in Hematology

Copyright © 2017 Kamia Thakur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. K. Matsumoto, “Oral extended-release oxymorphone: a new choice for chronic pain relief,” Expert Opinion on Pharmacotherapy, vol. 8, no. 10, pp. 1515–1527, 2007. View at Publisher · View at Google Scholar · View at Scopus
2. M. Wallace, C. Argoff, S. Babbar, M. Adera, and E. Carrazana, PAINWeek 2014 Accepted Abstracts 1 Efficacy and safety of NP-1998, a novel topical liquid formulation of capsaicin, in patients with postherpetic neuralgia: results of a phase 2, multi-center, placebo-controlled trial n.d.
3. N. Shusterman, F. Diana, C. Ciliberto et al., “(443) evaluation of the clinical abuse potential of Opana ER versus oxymorphone HCl powder,” The Journal of Pain, vol. 17, no. 4, article S85, 2016. View at Publisher · View at Google Scholar
4. Z. L. Al-Nouri, J. A. Reese, D. R. Terrell, S. K. Vesely, and J. N. George, “Drug-induced thrombotic microangiopathy: a systematic review of published reports,” Blood, vol. 125, no. 4, pp. 616–618, 2015. View at Publisher · View at Google Scholar · View at Scopus
5. E. Marder, D. Kirschke, D. Robbins et al., “Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012,” Morbidity and Mortality Weekly Report, 2013. View at Google Scholar
6. G. V. Karpova, E. V. Abramova, T. I. Lamzina, E. A. Timina, and T. V. Vetoshkina, “Myelotoxicity of high-molecular-weight poly(ethylene oxide),” Eksp Klin Farmakol n.d., vol. 67, pp. 61–65, 2004. View at Google Scholar
7. R. Hunt, A. Yalamanoglu, J. Tumlin et al., “A mechanistic investigation of thrombotic microangiopathy associated with intravenous abuse of Opana ER,” Blood, vol. 129, no. 7, pp. 896–905, 2016. View at Publisher · View at Google Scholar
8. M. Nataatmadja and D. Divi, “Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone,” Clinical Kidney Journal, vol. 9, no. 4, pp. 580–582, 2016. View at Publisher · View at Google Scholar
9. S. Baid, M. Pascual, A. B. Cosimi, R. T. Chung, R. B. Colvin, and N. Tolkoff-Rubin, “Viruses and thrombotic microangiopathy,” Transplantation, vol. 68, no. 5, pp. 710-711, 1999. View at Publisher · View at Google Scholar · View at Scopus
10. M. Yagita, M. Uemura, T. Nakamura, A. Kunitomi, M. Matsumoto, and Y. Fujimura, “Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura,” Journal of Hepatology, vol. 42, no. 3, pp. 420-421, 2005. View at Publisher · View at Google Scholar · View at Scopus
11. A. Zakarija and C. Bennett, “Drug-induced thrombotic microangiopathy,” Seminars in Thrombosis and Hemostasis, vol. 31, no. 6, pp. 681–690, 2005. View at Publisher · View at Google Scholar
12. X. Zheng, E. M. Majerus, and J. E. Sadler, “ADAMTS13 and TTP,” Current Opinion in Hematology, vol. 9, no. 5, pp. 389–394, 2002. View at Publisher · View at Google Scholar · View at Scopus
13. T. Ono, J. Mimuro, S. Madoiwa et al., “Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure,” Blood, vol. 107, no. 2, pp. 528–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
14. P. J. Miller, A. M. Farland, M. A. Knovich, K. M. Batt, and J. Owen, “Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange,” American Journal of Hematology, vol. 89, no. 7, pp. 695–697, 2014. View at Publisher · View at Google Scholar · View at Scopus